vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Perella Weinberg Partners (PWP). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $219.2M, roughly 1.3× Perella Weinberg Partners). Perella Weinberg Partners runs the higher net margin — 6.3% vs -45.7%, a 52.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -2.9%). Perella Weinberg Partners produced more free cash flow last quarter ($30.5M vs $-54.2M). Over the past eight quarters, Perella Weinberg Partners's revenue compounded faster (46.5% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
GH vs PWP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $219.2M |
| Net Profit | $-128.5M | $13.8M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 8.5% |
| Net Margin | -45.7% | 6.3% |
| Revenue YoY | 39.4% | -2.9% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $219.2M | ||
| Q3 25 | $265.2M | $164.6M | ||
| Q2 25 | $232.1M | $155.3M | ||
| Q1 25 | $203.5M | $211.8M | ||
| Q4 24 | $201.8M | $225.7M | ||
| Q3 24 | $191.5M | $278.2M | ||
| Q2 24 | $177.2M | $272.0M | ||
| Q1 24 | $168.5M | $102.1M |
| Q4 25 | $-128.5M | $13.8M | ||
| Q3 25 | $-92.7M | $6.0M | ||
| Q2 25 | $-99.9M | $2.7M | ||
| Q1 25 | $-95.2M | $17.3M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $16.4M | ||
| Q2 24 | $-102.6M | $-66.0M | ||
| Q1 24 | $-115.0M | $-35.8M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 8.5% | ||
| Q3 25 | -37.3% | 5.4% | ||
| Q2 25 | -45.9% | 5.8% | ||
| Q1 25 | -54.6% | 5.5% | ||
| Q4 24 | -62.4% | — | ||
| Q3 24 | -61.3% | 12.9% | ||
| Q2 24 | -56.8% | -30.2% | ||
| Q1 24 | -59.2% | -52.4% |
| Q4 25 | -45.7% | 6.3% | ||
| Q3 25 | -35.0% | 3.6% | ||
| Q2 25 | -43.0% | 1.8% | ||
| Q1 25 | -46.8% | 8.2% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | 5.9% | ||
| Q2 24 | -57.9% | -24.3% | ||
| Q1 24 | -68.2% | -35.1% |
| Q4 25 | $-1.01 | $0.11 | ||
| Q3 25 | $-0.74 | $0.08 | ||
| Q2 25 | $-0.80 | $0.04 | ||
| Q1 25 | $-0.77 | $0.24 | ||
| Q4 24 | $-0.90 | — | ||
| Q3 24 | $-0.88 | $0.24 | ||
| Q2 24 | $-0.84 | $-1.21 | ||
| Q1 24 | $-0.94 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $255.9M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $-127.4M |
| Total Assets | $2.0B | $797.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $255.9M | ||
| Q3 25 | $580.0M | $185.5M | ||
| Q2 25 | $629.1M | $145.0M | ||
| Q1 25 | $698.6M | $111.2M | ||
| Q4 24 | $525.5M | $407.4M | ||
| Q3 24 | $585.0M | $335.1M | ||
| Q2 24 | $933.7M | $185.3M | ||
| Q1 24 | $1.0B | $156.7M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $-127.4M | ||
| Q3 25 | $-354.5M | $-302.4M | ||
| Q2 25 | $-305.5M | $-318.4M | ||
| Q1 25 | $-250.8M | $-323.1M | ||
| Q4 24 | $-139.6M | $-421.4M | ||
| Q3 24 | $-60.1M | $-360.8M | ||
| Q2 24 | $-1.6M | $-283.0M | ||
| Q1 24 | $68.3M | $161.9M |
| Q4 25 | $2.0B | $797.6M | ||
| Q3 25 | $1.3B | $650.2M | ||
| Q2 25 | $1.3B | $606.7M | ||
| Q1 25 | $1.3B | $570.5M | ||
| Q4 24 | $1.5B | $876.8M | ||
| Q3 24 | $1.5B | $810.9M | ||
| Q2 24 | $1.6B | $645.5M | ||
| Q1 24 | $1.7B | $583.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $34.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $30.5M |
| FCF MarginFCF / Revenue | -19.3% | 13.9% |
| Capex IntensityCapex / Revenue | 9.9% | 2.0% |
| Cash ConversionOCF / Net Profit | — | 2.52× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-34.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $34.8M | ||
| Q3 25 | $-35.4M | $59.2M | ||
| Q2 25 | $-60.3M | $56.1M | ||
| Q1 25 | $-62.7M | $-176.5M | ||
| Q4 24 | $-64.5M | $223.4M | ||
| Q3 24 | $-51.1M | $200.3M | ||
| Q2 24 | $-94.0M | $90.0M | ||
| Q1 24 | $-30.3M | $-206.3M |
| Q4 25 | $-54.2M | $30.5M | ||
| Q3 25 | $-45.8M | $57.6M | ||
| Q2 25 | $-65.9M | $55.3M | ||
| Q1 25 | $-67.1M | $-177.6M | ||
| Q4 24 | $-83.4M | $207.0M | ||
| Q3 24 | $-55.3M | $199.3M | ||
| Q2 24 | $-99.1M | $83.7M | ||
| Q1 24 | $-37.2M | $-214.8M |
| Q4 25 | -19.3% | 13.9% | ||
| Q3 25 | -17.3% | 35.0% | ||
| Q2 25 | -28.4% | 35.6% | ||
| Q1 25 | -33.0% | -83.8% | ||
| Q4 24 | -41.3% | 91.7% | ||
| Q3 24 | -28.9% | 71.6% | ||
| Q2 24 | -55.9% | 30.8% | ||
| Q1 24 | -22.1% | -210.3% |
| Q4 25 | 9.9% | 2.0% | ||
| Q3 25 | 3.9% | 0.9% | ||
| Q2 25 | 2.4% | 0.5% | ||
| Q1 25 | 2.2% | 0.5% | ||
| Q4 24 | 9.4% | 7.3% | ||
| Q3 24 | 2.2% | 0.4% | ||
| Q2 24 | 2.9% | 2.3% | ||
| Q1 24 | 4.1% | 8.3% |
| Q4 25 | — | 2.52× | ||
| Q3 25 | — | 9.85× | ||
| Q2 25 | — | 20.50× | ||
| Q1 25 | — | -10.18× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 12.23× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PWP
Segment breakdown not available.
